NewLimit

NewLimit is a startup based in All. Its most recent tracked round is Series-c-plus. Brouky records 1 investor associated with the company.

NewLimit is inventing medicines to radically extend healthy human lifespan by reversing cellular aging through epigenetic reprogramming. They use an AI-driven discovery engine to design and test transcription-factor payloads that restore youthful function in old cells, with initial programs targeting the liver, immune system, and vasculature.